Chemical inhibitors of C1orf149 include a range of compounds that target various signaling pathways and cellular processes which are integral to the function of this protein. Palbociclib, which targets CDK4/6 involved in cell cycle progression, can inhibit the proliferative processes that C1orf149 may regulate. Similarly, the compound Trametinib, a MEK1/2 inhibitor, disrupts the MAPK pathway signaling, which is often critical for the regulation of growth and differentiation that C1orf149 might influence. LY294002, another inhibitor in this collection, targets PI3K, thus attenuating the PI3K/AKT signaling pathway, which plays a pivotal role in a multitude of cellular processes including those regulated by C1orf149. When Src family kinases are inhibited by Dasatinib, it can lead to the disruption of downstream signaling pathways that may involve C1orf149 in cell regulation mechanisms.
Continuing with the arsenal of chemical inhibitors, U0126 and SB203580 specifically inhibit MEK1/2 and p38 MAPK, respectively, and these inhibitions can impede the ERK and stress response pathways, which are potentially vital for the functional activity of C1orf149. Rapamycin, by inhibiting mTOR, can impair processes such as growth and proliferation, which might be under the regulatory umbrella of C1orf149. The JNK pathway, implicated in apoptosis and cell growth, can be inhibited by SP600125, possibly affecting C1orf149's role in these pathways. Additionally, multi-tyrosine kinase inhibitors like Sorafenib and Sunitinib can disrupt angiogenesis and growth factor signaling, thereby inhibiting the physiological contexts in which C1orf149 operates. Wortmannin, another PI3K inhibitor, serves to further disrupt the AKT pathway, curtailing the cellular processes potentially influenced by C1orf149. Lastly, ZM-447439 inhibits Aurora kinases and can disrupt cell cycle progression and mitotic events, processes where C1orf149 could play a regulatory role. Each of these inhibitors targets specific pathways or cellular processes to exert their inhibitory effects on the function of C1orf149.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Inhibits CDK4/6 involved in cell cycle progression, which could be essential for C1orf149-related processes. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Inhibits MEK1/2 in the MAPK pathway, potentially crucial for signaling processes involving C1orf149. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, disrupting downstream signaling that might be necessary for C1orf149 function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits Src family kinases, possibly affecting signaling pathways regulating C1orf149 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, potentially affecting stress response pathways that involve C1orf149. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which might be necessary for C1orf149-related processes like growth and proliferation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which may be involved in apoptotic and growth pathways related to C1orf149. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple tyrosine kinases, potentially affecting angiogenesis and growth pathways involving C1orf149. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Inhibits receptor tyrosine kinases, which could affect growth factor signaling related to C1orf149. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3K, potentially disrupting the PI3K/AKT pathway on which C1orf149 may rely. | ||||||